SEGMENT INFORMATION (Tables)

9 Months Ended

Jul. 31, 2022


	For the Three Months Ended July 31,						For the nine Months Ended July 31,
	2022			2021			2022			2021
Net Loss:
CAR-T Therapeutics	$	(965	)	$	(1,619	)	$	(3,975	)	$	(4,025	)
Cancer Vaccines		(903	)		(1,464	)		(3,684	)		(3,033	)
Anti-Viral Therapeutics		(904	)		(1,262	)		(2,565	)		(2,053	)
Other		(3	)		(43	)		(18	)		54
Total	$	(2,775	)	$	(4,388	)	$	(10,242	)	$	(9,057	)
Net Loss	$	(2,775	)	$	(4,388	)	$	(10,242	)	$	(9,057	)

Total operating costs and expenses	$	2,797		$	4,388		$	10,266		$	9,572
Less non-cash share-based compensation		(1,438	)		(3,187	)		(5,474	)		(5,225	)
Operating costs and expenses excluding non-cash share-based compensation	$	1,359		$	1,201		$	4,792		$	4,347
Operating costs and expenses excluding non-cash share based compensation:
CAR-T Therapeutics	$	425		$	411		$	1,852		$	1,904
Cancer Vaccines		378			349			1,598			1,185
Anti-Viral Therapeutics		554			418			1,328			827
Other		2			23			14			431
Total	$	1,359		$	1,201		$	4,792		$	4,347
Operating costs and expenses excluding non-cash share based compensation	$	1,359		$	1,201		$	4,792		$	4,347